The recent first global approval of brigatinib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC”
The recent first global approval of valbenazine has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia”
The recent first global approval of cerliponase alfa has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2”
The recent first global approval of ocrelixumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS”
The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema”
Continue reading “Live webinar: The EMA’s MLM service and options for integration”
